2025-12-23 - Analysis Report
Okay, here's a report on Northrop Grumman (NOC) based on the provided data, with simple numbers and then analysis.

**1) Return Rate Comparison**

*   **Company Overview:** Northrop Grumman Corp. is a leading global aerospace and defense technology company.
*   **NOC Cumulative Return:** 47.50%
*   **VOO (S&P 500) Cumulative Return:** 100.88%
*   **Divergence:**
    *   Current Divergence: -53.38% (NOC is underperforming VOO by 53.38% cumulatively).
    *   Divergence Range: -59.4% to 56.8%
    *   Relative Divergence: 5.2% (Indicates NOC's divergence is near its lowest point relative to its historical range).

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|------------|--------|-------|--------|------|--------|
| 2015-2017  | 46.0%  | 65.6% | 17.0%  | 0.0  | 45.2   |
| 2016-2018  | -2.0%  | 74.3% | -17.0% | 0.0  | 36.1   |
| 2017-2019  | 17.0%  | 79.2% | -5.0%  | 0.9  | 50.6   |
| 2018-2020  | -28.0% | 79.9% | -52.0% | 0.8  | 44.9   |
| 2019-2021  | 43.0%  | 79.9% | -4.0%  | 0.8  | 57.0   |
| 2020-2022  | 18.0%  | 79.9% | 19.0%  | 0.3  | 80.3   |
| 2021-2023  | 24.0%  | 82.7% | 23.0%  | 0.2  | 68.9   |
| 2022-2024  | -15.0% | 82.7% | -36.0% | 0.2  | 69.1   |
| 2023-2025  | -3.0%  | 82.1% | -68.0% | 0.1  | 83.7   |

*   **Analysis:** NOC has significantly underperformed the S&P 500 over the period examined. The Alpha (risk-adjusted performance) is mostly negative, indicating underperformance relative to the market. Beta is low, indicating lower volatility than the market. The Maximum Drawdown (MDD) values are very high, showing substantial potential losses. CAGR fluctuates, indicating inconsistency.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 568.46
*   **Last Market Data:** Price 584.66, Previous Close 568.46, Change +2.85%
*   **5-day SMA:** 567.34
*   **20-day SMA:** 560.77
*   **60-day SMA:** 581.32

*   **Analysis:** The price has slightly increased, breaking through 5-day SMA and 20-day SMA.

**3) Technical Indicators and Expected Return**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI:** 65.35 (Approaching overbought territory, but not quite there)
*   **PPO:** 0.39 (Positive, suggesting upward momentum)
*   **Hybrid Signal:** Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Dividend_2.31 Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Relative Divergence Change (20 days):** -0.5 (Short-term decline)
*   **Expected Return:** -151.2% (Very negative, suggesting significant underperformance compared to the S&P 500 over the long term).

**4) Recent News & Significant Events**

*   **Key Themes:**
    *   **Valuation discussions:** Several articles focus on Northrop Grumman's valuation, suggesting it might be overvalued after a strong year-to-date run earlier in December.
    *   **Earnings Release:** Upcoming earnings release date is announced.
    *   **Contract Wins:** Northrop Grumman secured a $100M missile weapon system contract.
    *   **Institutional Selling:** Texas Permanent School Fund Corp sold shares of NOC.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean 2.04)
*   **Target Price:** Average 662.68 (Suggesting upside potential from the current price).
* Recent Rating Changes:  No Data

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue        |
|------------|------|----------------|
| 2025-10-21 | 7.69 | 10.42 B$       |
| 2025-07-22 | 8.17 | 10.35 B$       |
| 2025-04-22 | 3.33 | 9.47 B$        |
| 2024-10-24 | 7.02 | 10.00 B$       |
| 2025-10-21 | 7.02 | 10.00 B$       |

*   **Analysis:** Revenue is fairly consistent, but EPS is showing some volatility. The most recent EPS is higher than the value a year prior. The 2025-04-22 EPS figure is significantly lower, and might warrant further investigation. Note: There are two duplicated data for 2025-10-21.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-09-30 | $10.42B    | 21.37%        |
| 2025-06-30 | $10.35B    | 21.35%        |
| 2025-03-31 | $9.47B     | 16.69%        |
| 2024-12-31 | $10.69B    | 18.08%        |
| 2024-09-30 | $10.00B    | 21.07%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE   |
|------------|------------|-------|
| 2025-09-30 | $15.99B    | 6.88% |
| 2025-06-30 | $15.47B    | 7.59% |
| 2025-03-31 | $14.98B    | 3.21% |
| 2024-12-31 | $15.29B    | 8.27% |
| 2024-09-30 | $14.75B    | 6.96% |

*   **Analysis:** Revenue is generally stable. Profit margins are relatively high and fairly consistent, though there was a dip in Q1 2025. Equity has been increasing, and ROE is generally good but fluctuates alongside profit margin.

**7) Comprehensive Analysis**

*   **Underperformance:** NOC has significantly underperformed the S&P 500, and the expected return suggests this underperformance is projected to continue.
*   **Mixed Signals:** Technical indicators are mixed. The RSI is nearing overbought, but the PPO shows positive momentum. The MRI indicates a medium level of investment risk.
*   **Analyst Optimism vs. Data:** While analysts have a "Buy" consensus and target price suggesting upside, the underlying data paints a more cautious picture. The news highlights valuation concerns and institutional selling.
*   **Earnings Consistency:** Revenue is fairly consistent, but EPS and Profit Margin show some volatility.
*   **Recommendation:** Based on the provided data, a cautious approach is warranted. While analysts are optimistic, the underperformance relative to the S&P 500, the negative expected return, and valuation concerns highlighted in the news suggest potential risks. Further due diligence is recommended before investing.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.